Peter Forsyth, MD, discusses a first-in-human trial of intrathecal dendritic cell therapy for leptomeningeal disease from breast cancer.
|Videos|December 12, 2017
Preserving Fertility in Breast Cancer Patients After Chemotherapy
Author(s)Kathryn J. Ruddy, MD, MPH
This video highlights four abstracts from SABCS on preserving fertility in premenopausal breast cancer patients treated with chemotherapy.
Advertisement
In this video, Kathryn J. Ruddy, MD, MPH, of the Mayo Clinic in Rochester, Minnesota, discusses four abstracts on preserving fertility in premenopausal breast cancer patients treated with chemotherapy.
Ruddy was a discussant for a spotlight session on this topic at the 2017 San Antonio Breast Cancer Symposium (SABCS), held December 5–9 in San Antonio, Texas.
Advertisement
Related to this article
Adding radiotherapy to tislelizumab and chemotherapy also appeared to prolong progression-free survival in a real-world setting.
![“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/06df696db42b151710c58727b1333ee098de6453-1200x800.jpg?w=350&fit=crop&auto=format)
“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.
At SOHO 2026, experts highlighted new findings and advances across diseases including lymphoma, myelodysplastic syndrome, and leukemia.
Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
!["Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1cfb57db416943d8f8690afb0bc0d13aa3d90683-400x400.jpg?w=350&fit=crop&auto=format)
"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.
Posters highlighted sex-based differences in aggressive B-cell NHL, third-line therapies in aggressive BCL, and real-world safety with CD20/CD3 bispecifics.
Subcutaneous amivantamab is safer and more convenient for patients compared with the intravenous formulation, according to Misako Nagasaka, MD, PhD.
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
2
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
3
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
4
COA Warns That Price Negotiation for Medicare Part B Drugs Threatens Community Oncology
5